secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001104659-23-114582
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Biotherapeutics (fka Vaccitech) begins trading under BRNS, presents Phase 2 HBV data
--------------------------------------------------------------------------------

- Company renamed to Barinthus Biotherapeutics; Nasdaq ticker changes from VACC to BRNS effective Nov 7, 2023.
- Phase 2 hepatitis B trial data for VTP-300 to be presented at AASLD Liver Meeting Nov 10-14, including combination with imdusiran.
- Shareholders approved resolutions authorizing directors to allot shares up to £1,928 nominal and disapply pre-emption rights.
- Strategic shift from vaccines to T cell immunotherapies targeting chronic infectious diseases, autoimmunity, and cancer.
- Clinical collaboration with Arbutus Biopharma highlighted in late-breaking abstract on VTP-300 plus imdusiran.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923114582/0001104659-23-114582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923114582/tm2329836d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-114582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer